{"id":251963,"date":"2023-06-15T00:00:00","date_gmt":"2023-06-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidcg0084-biopharma-alzheimers-disease-epidemiology-epidemiology\/"},"modified":"2026-04-27T23:25:29","modified_gmt":"2026-04-27T23:25:29","slug":"epidcg0084-biopharma-alzheimers-disease-epidemiology-epidemiology-dashboard","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcg0084-biopharma-alzheimers-disease-epidemiology-epidemiology-dashboard\/","title":{"rendered":"Alzheimer&#8217;s Disease &#8211; Epidemiology &#8211; Epidemiology Dashboard"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of alzheimer&#8217;s disease comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of alzheimer&#8217;s disease for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.<\/p>\n<p>All forecast data are available on Clarivate\u2019s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology&#8217;s alzheimer&#8217;s disease forecast answers the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of alzheimer&#8217;s disease and the number of new diagnoses of alzheimer&#8217;s disease?<\/li>\n<li>Of all people diagnosed with alzheimer&#8217;s disease, how many in each country across the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of alzheimer&#8217;s disease over the forecast period?<\/li>\n<\/ul>\n<p>In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following alzheimer&#8217;s disease subpopulations:<\/p>\n<ul class=\"round-bullets\">\n<li>Asymptomatic AD prevalent cases.<\/li>\n<li>Total MCI due to AD prevalent cases.<\/li>\n<li>Asymptomatic AD incident cases.<\/li>\n<li>Total MCI due to AD incident cases.<\/li>\n<li>Total AD incident cases.<\/li>\n<li>Diagnosed AD prevalent cases.<\/li>\n<li>Diagnosed MCI due to AD prevalent cases.<\/li>\n<li>Diagnosed AD prevalent cases by symptom status (agitation, depression, hallucinations).<\/li>\n<li>Diagnosed AD prevalent cases by severity<\/li>\n<li>Diagnosed drug-treated AD prevalent cases.<\/li>\n<li>Diagnosed drug-treated mild AD prevalent cases.<\/li>\n<li>Diagnosed drug-treated moderate AD prevalent cases.<\/li>\n<li>Diagnosed drug-treated severe AD prevalent cases.<\/li>\n<\/ul>\n<p>\u2026 and many more (details available on request).<\/p>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251963","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-alzheimers-disease","biopharma-therapy-areas-neurology","biopharma-product-epidemiology","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251963","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251963\/revisions"}],"predecessor-version":[{"id":305348,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251963\/revisions\/305348"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251963"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}